대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
저자	Yong Chul Kim1, Jung Nam An2, Jin Hyuk Kim2, Young-Wook Choi2, Chun Soo Lim2, Yon Su Kim1, Seung Hee Yang3, Jung Pyo Lee2
출판정보	2018; 2018(1):
키워드	urinary cMet \| diabetic nephropathy \| end stage renal disease
초록	Objectives: Hepatocyte growth factor and its receptor cMet activate biological pathways necessary for repair and regeneration following kidney injury. Here, we evaluated the clinical role of urinary cMet as a prognostic biomarker in diabetic nephropathy (DN). Methods: A total of 218 patients with DN were enrolled in this study. We examined the association of urine cMet levels and long-term outcomes in patients with DN. Results: The levels of urinary cMet were higher in patients with decreased renal function than in patients with relatively preserved renal function (5.17 ± 9.56 ng/ml versus 1.86 ± 4.85 ng/ml, P = 0.001). A fully adjusted model revealed that a urinary cMet cutoff of 2.9 ng/mL was associated with a hazard ratio for end-stage renal disease of 2.50 (95% confidence interval 1.18–4.53, P = 0.007). The addition of urinary cMet to serum creatinine and proteinuria provided the highest net reclassification improvement. We found that in primary cultured human glomerular endothelial cells, TGFβ treatment induced fibrosis, and the protein expression levels of collagen IV, fibronectin, and αSMA were decreased after administration of an agonistic cMet antibody. Conclusions: In conclusion, elevated levels of urinary cMet at the time of initial diagnosis could predict renal outcomes in patients with DN.
원문(PDF)	PDF 원문보기

목록

위로가기